Regenetp (STU:NJT) Change In Working Capital : €-2.42 Mil (TTM As of Mar. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Regenetp Change In Working Capital?

Regenetp's change in working capital for the quarter that ended in Mar. 2023 was €-0.49 Mil.

Regenetp's change in working capital for the fiscal year that ended in Dec. 2022 was €-0.47 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Regenetp Change In Working Capital Historical Data

The historical data trend for Regenetp's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Change In Working Capital Chart

Regenetp Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

-0.16

0.26

-4.49

0.70

-0.47

Regenetp Quarterly Data
	Apr18	Jul18	Oct18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Working Capital	Get a 7-Day Free Trial															1.42	-2.27	0.44	-0.10	-0.49

Regenetp Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.42 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Regenetp Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Regenetp's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (STU:NJT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

RGTPQ:USA

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines